Highlights

  • BlinkLab (ASX:BB1) jumped 25.37% as its US regulatory program remained the central catalyst.
  • The pivotal BlinkLab Dx1 study is designed to support an FDA 510(k) submission.
  • The study will enrol at least 528 children across 10 US clinical sites.
  • Earlier US pilot data reported 83.7% sensitivity and 84.7% specificity for autism.

BlinkLab (ASX:BB1) has gained 25.37% as its digital autism-diagnostic program moves from early validation into a larger regulatory study. The company has assembled a 10-site US clinical network and commenced the pivotal program designed to support an FDA 510(k) submission for BlinkLab Dx1. With a Market Capitalisation of about AUD 128.74mn, BlinkLab sits firmly in small-cap territory, but the next milestones are increasingly clinical and regulatory rather than conceptual.

Pivotal FDA Study Is the Main Program

BlinkLab’s pivotal study is intended to validate both usability and diagnostic accuracy for BlinkLab Dx1. The program is expected to enrol at least 528 children aged two to eleven across 10 US sites.

The first participant was enrolled in March 2026, moving the company into the formal validation phase of its FDA pathway.

Pilot Data Set a Higher Benchmark

The pivotal program follows a US pilot study involving 485 children. BlinkLab reported sensitivity of 83.7% and specificity of 84.7%, above the performance thresholds agreed with the FDA for the next study.

Those results provide a useful starting point, but they still need to be reproduced in the pivotal population.

ADHD Adds a Second Development Pathway

BlinkLab is also preparing BlinkLab Dx2 for ADHD assessment. The company has raised capital to support both the autism launch pathway and expansion of the ADHD clinical program.

That creates a broader platform opportunity if the core technology can be validated across multiple neurodevelopmental conditions.

What to Watch

Recruitment progress, pivotal-study data, FDA submission timing and development of BlinkLab Dx2 are the main catalysts.

Risks

Pivotal results may not match pilot-study performance. FDA clearance is not guaranteed, commercial adoption remains unproven and further capital could be required.